A bis-benzylisoquinoline alkaloid.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status

Natural product

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Tetrandrine is a bis-benzylisoquinoline alkaloid. It has been reported to act as a calcium channel blocker and shown to possess anti-SARS-CoV-2 activity in vitro (He et al., 2021).

Tetrandrine on DrugBank
Tetrandrine on PubChem
Tetrandrine on Wikipedia


SC182; Fanchinine; Sinomenine A; Hanfangchin A


Structure image - Tetrandrine


Supporting references

Link Tested on Impact factor Notes Publication date
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19
Preprint In vitro Screening
HeLa-ACE2 cells Jun/16/2020
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Small molecule In vitro Screening
Vero cells 5.09 Nov/25/2020
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Small molecule In vitro Screening
Vero E6 cells 42.78 Jul/24/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
Calu-3 human airway epithelial cells

higher IC50 value in Calu-3 cells than VERO E6 cells

Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products
Small molecule In vitro Mechanism
in vitro binding assay; 293T-ACE2 cells; Calu-3 cells; A549 cells; Vero E6 cells; (HIV-1) SARS-CoV-2 Spike (D614/G614/B.1.1.7/B.1.351); SARS-CoV-2 live virus 13.49

Tetrandrine inhibited lentiviral SARS-CoV-2 Spike-pseudotyped virus infection in 293T-ACE2 (EC50 of 0.9 μM or lower, SI >55), Calu-3 and A549 cells. It displayed efficacy also against pseudoviruses with Spike protein of G614, B.1.1.7, B.1.351, SARS, and MERS viruses/strains. The experimental findings suggest that the compound blocks coronavirus entry into host cells by inhibition of calcium ion channels. The compound was also shown to protect Vero E6 cells from SARS-CoV-2 live virus-induced cytopathogenic effect.


AI-suggested references

Clinical trials

ID Title Status Phase Start date Completion date
NCT04308317 Tetrandrine Tablets Used in the Treatment of COVID-19 Unknown status Phase 4 Mar/05/2020 May/01/2021
  • Alternative id - TT-NPC
  • Interventions - Drug: Tetrandrine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Tetrandrine Tablets, Jinhua, Zhejiang, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Survival rate|body temperature